ClinicalTrials.gg
RecruitingNCT07541170KRASCENDO 3Updated Nov 9, 2026

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of Divarasib and Pembrolizumab in Non-small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Recruiting at 104 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 9, 2026First sites in 13 new countriesStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche — 5 open to participants now, 16 under way, 8 of them phase 3. Carcinoma, Non-Small-Cell Lung · Hoffmann-La Roche.

Planned enrollment
37th of 142
400 · median 136
Started
2026
with 1 other
Phase 3
48 of 182
2 open now
Primary completion
2032-01
later than 13 of 15 live
Registered
180th of 182
by date

Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 37th largest by planned enrollment of the 142 interventional ones that give a count, is one of 2 that started in 2026, is one of 48 in phase 3, reaches primary completion later than 13 of the 15 other live ones, and was the 180th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolumab) or observation in participants with resected Kirsten rat sarcoma viral oncogene homolog glycine 12 to cysteine (KRAS G12C)-positive Stage II-IIIB NSCLC, regardless of tumor programmed death-ligand 1 (PD-L1) status, who have not achieved pathologic complete response (pCR) following neoadjuvant chemoimmunotherapy.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status of 0 or 1
  • Histological or cytological diagnosis of clinical Stage II-IIIB NSCLC of either non-squamous or squamous histology
  • Participants must have had complete resection of NSCLC
  • Prior treatment with (pembrolizumab or nivolumab) in combination with histology-based platinum-based doublet chemotherapy
  • Participants must be randomized within 12 weeks of their surgery date
  • No evidence of disease recurrence or disease
  • Documentation of the presence of a KRAS G12C mutation

Exclusion criteria

Exclusion Criteria:

  • Participants who achieve pCR following treatment
  • Prior treatment with a KRAS inhibitor or any other anti-cancer therapy not otherwise specified in the protocol
  • Prior treatment with radiation therapy for NSCLC, with the exception of localized symptom-directed radiation prior to surgical resection
  • Resolved Grade 3 or greater immune-related AE or unresolved Grade 2 or greater immune-related AE from neoadjuvant immunotherapy
  • Active or history of disease or immune deficiency
  • Significant cardiovascular disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Divarasib

    Participants will receive divarasib, orally (PO), once daily (QD) for up to 52 cycles (1 cycle = 21 days).

    Drug: Divarasib

  • Active comparator
    Control: Pembrolizumab or Nivolumab or Observation

    Participants will receive either pembrolizumab, nivolumab, or undergo observation, depending on the treatment received prior to surgery. No study treatment will be given to participants who will undergo observation.

    Drug: Pembrolizumab · Drug: Nivolumab

Interventions

  • Divarasib will be administered orally as per the schedule specified in the respective arm.

    Also known as: RO743584; GDC-6036

  • Pembrolizumab will be administered as either a 200 mg intravenous (IV) infusion, every 3 weeks (Q3W) or 395 mg subcutaneous (SC) injection Q3W, for up to 13 cycles (1 cycle = 21 days).

    Also known as: Keytruda

  • Nivolumab will be administered as either a 480 mg IV infusion, every 4 weeks (Q4W) or 1200 mg SC injection Q4W, for up to 13 cycles (1 cycle = 28 days).

    Also known as: Opdivo

06

What researchers measure

Primary outcomes

  1. Disease-free Survival (DFS), as Determined by the Investigator

    Time frame: From randomization to disease recurrence or death from any cause (Up to approximately 5 years)

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: From date of randomization to death from any cause (up to approximately 8 years)

  2. DFS Rates at 2 and 3 Years, as Assessed by the Investigator

    Time frame: At Year 2 and Year 3

  3. Number of Participants With Adverse Events (AEs)

    Time frame: From randomization to 60 days after the end of study treatment (up to approximately 8 years)

07

Study locations

103 of 104 sites recruiting

Showing the first 100 of 104 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jan 2032, 63 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 63 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 21, 2026
StartActual
Oct 6, 2026was Sep 2026
Primary completionEst.
Jan 31, 2032
CompletionEst.
Mar 31, 2035
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
85 sites added — first sites in Canada, China, Colombia, Greece, Japan and 8 more
All 13 countries

Canada, China, Colombia, Greece, Japan, Poland, Portugal, Spain, Belgium, France, Germany, Ireland, United Kingdom

Show 85 added (17 China, 12 Spain, 7 South Korea, 6 Poland, 5 United States, 5 Italy, 4 Colombia, 4 Greece, 4 Japan, 4 France, 4 Germany, 3 Portugal, 2 Brazil, 2 Canada, 2 Belgium, 2 Ireland, 1 Argentina, 1 United Kingdom)
  • Renown Regional Medical Center · Reno, United States
  • Hospital Privado De Comunidad · Mar del Plata, Argentina
  • Hospital Moinhos de Vento · Porto Alegre, Brazil
  • Beneficencia Portuguesa de Sao Paulo · São Paulo, Brazil
  • Jewish General Hospital · Montreal, Canada
  • Guangdong General Hospital · Guangzhou, China
  • Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo · Bogota, D.C., Colombia
  • Clinica ASTORGA · Medellín, Colombia
  • Attikon University General Hospital · Athens, Greece
  • Athens Medical Center · Marousi, Greece
  • Gifu University Hospital · Gifu, Japan
  • Kobe University Hospital · Hyōgo, Japan
  • Centrum Pulmonologii i Torakochirurgii · Bystra, Poland
  • Uniwersyteckie Centrum Kliniczne, O?rodek Bada? Klinicznych Wczesnych Faz · Gda?sk, Poland
  • ?wi?tokrzyskie Centrum Onkologii Samodzielny Publiczny Zak?ad Opieki Zdrowotnej w Kielcach;Klinika Onkologii Klinicznej · Kielce, Poland
  • Centro Clinico Champalimaud · Lisbon, Portugal
  • Seoul National University Bundang Hospital · Seongnam-si, South Korea
  • Yeungnam University Medical Center · Daegu, South Korea
  • Chungnam National University Hospital · Daejeon, South Korea
  • Ajou University Medical Center · Gyeonggi-do, South Korea
  • Severance Hospital, Yonsei University Health System · Seoul, South Korea
  • Asan Medical Center · Seoul, South Korea
  • Hospital de Basurto · Bilbao, Spain
  • Complejo Hospitalario Universitario A Coruña (CHUAC) · A Coruña, Spain
  • Hospital General Univ. de Alicante · Alicante, Spain
  • Hospital Universitario San Cecilio · Granada, Spain
  • Hospital Universitario Miguel Servet · Zaragoza, Spain
  • Bay Pines VA Healthcare System · Bay Pines, United States
  • Dana-Farber Cancer Institute · Boston, United States
  • The James Cancer Hospital and Solove Research Institute · Columbus, United States
  • …and 55 more on the registry record
across 2 updates, Oct 13, 2026 – Nov 9, 2026
Start date
Sep 30, 2026→Oct 6, 2026 (actual)
Oct 13, 2026
Show all 2 updates
  1. Nov 9, 2026
    58 sites added — first sites in Belgium, France, Germany, Ireland and United Kingdom
    Show 58 added (16 China, 7 Spain, 5 Italy, 4 United States, 4 France, 4 Germany, 3 Poland, 2 Belgium, 2 Colombia, 2 Greece, 2 Ireland, 2 Japan, 2 Portugal, 1 Canada, 1 South Korea, 1 United Kingdom)
    • Bay Pines VA Healthcare System · Bay Pines, United States
    • Dana-Farber Cancer Institute · Boston, United States
    • The James Cancer Hospital and Solove Research Institute · Columbus, United States
    • Baptist Clinical Research Institute · Memphis, United States
    • Jessa Zkh (Campus Virga Jesse) · Hasselt, Belgium
    • CHU HELORA - Hôpital de Mons - Site Kennedy · Mons, Belgium
    • McGill University Health Center · Montreal, Canada
    • Anhui Provincial Hospital(The First Affiliated Hospital of USTC) · Hefei, China
    • Shenzhen People's Hospital · Shenzhen, China
    • Shandong Provincial Hospital · Jinan, China
    • Cancer Hospital of Shandong First Medical University · Jinan, China
    • Sichuan Cancer Hospital · Chengdu, China
    • Sir Run Run Shaw Hospital Zhejiang University School of Medicine - Qingchun Campus · Hangzhou, China
    • Beijing Cancer Hospital · Beijing, China
    • The First Hospital of Jilin University · Changchun, China
    • The First People's Hospital of Foshan · Foshan, China
    • The Second Affiliated Hospital of Zhejiang University College · HangzhouZhejiang, China
    • The Second Affiliated Hospital of Nanchang University · Nanchang, China
    • The First Affiliated Hospital of Nanchang University · Nanchang, China
    • Nanjing First Hospital · Nanjing, China
    • The First Affiliated Hospital of Soochow University · Suzhou, China
    • Taizhou Hospital Of Zhejiang Province · Taizhou, China
    • Tianjin Cancer Hospital · Tianjin, China
    • Clinica Bonnadona Prevenir · Barranquilla, Colombia
    • FOSCAL · Florindablanca, Colombia
    • CH d Avignon · Avignon, France
    • CH de Cornouailles · Quimper, France
    • CHU de Reims · Reims, France
    • Hôpital Foch · Suresnes, France
    • Vivantes Klinikum Neukölln;Klinik für Innere Medizin ? Hämatologie, Onkologie und Palliativmedizin · Berlin, Germany
    • …and 28 more on the registry record
    + 1 other change: verification date
  2. Oct 13, 2026
    27 sites added — first sites in Canada, China, Colombia, Greece, Japan and 3 more
    All 8 countries

    Canada, China, Colombia, Greece, Japan, Poland, Portugal, Spain

    Show 27 added (6 South Korea, 5 Spain, 3 Poland, 2 Brazil, 2 Colombia, 2 Greece, 2 Japan, 1 United States, 1 Argentina, 1 Canada, 1 China, 1 Portugal)
    • Renown Regional Medical Center · Reno, United States
    • Hospital Privado De Comunidad · Mar del Plata, Argentina
    • Hospital Moinhos de Vento · Porto Alegre, Brazil
    • Beneficencia Portuguesa de Sao Paulo · São Paulo, Brazil
    • Jewish General Hospital · Montreal, Canada
    • Guangdong General Hospital · Guangzhou, China
    • Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo · Bogota, D.C., Colombia
    • Clinica ASTORGA · Medellín, Colombia
    • Attikon University General Hospital · Athens, Greece
    • Athens Medical Center · Marousi, Greece
    • Gifu University Hospital · Gifu, Japan
    • Kobe University Hospital · Hyōgo, Japan
    • Centrum Pulmonologii i Torakochirurgii · Bystra, Poland
    • Uniwersyteckie Centrum Kliniczne, O?rodek Bada? Klinicznych Wczesnych Faz · Gda?sk, Poland
    • ?wi?tokrzyskie Centrum Onkologii Samodzielny Publiczny Zak?ad Opieki Zdrowotnej w Kielcach;Klinika Onkologii Klinicznej · Kielce, Poland
    • Centro Clinico Champalimaud · Lisbon, Portugal
    • Seoul National University Bundang Hospital · Seongnam-si, South Korea
    • Yeungnam University Medical Center · Daegu, South Korea
    • Chungnam National University Hospital · Daejeon, South Korea
    • Ajou University Medical Center · Gyeonggi-do, South Korea
    • Severance Hospital, Yonsei University Health System · Seoul, South Korea
    • Asan Medical Center · Seoul, South Korea
    • Hospital de Basurto · Bilbao, Spain
    • Complejo Hospitalario Universitario A Coruña (CHUAC) · A Coruña, Spain
    • Hospital General Univ. de Alicante · Alicante, Spain
    • Hospital Universitario San Cecilio · Granada, Spain
    • Hospital Universitario Miguel Servet · Zaragoza, Spain
    Start date Sep 30, 2026→Oct 6, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07541170
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Oct 6, 2026
Primary completion
Jan 31, 2032 (estimated)
Completion
Mar 31, 2035 (estimated)
Last update
Nov 9, 2026

Study contacts

Reference Study ID Number: BO45885 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Divarasib

Start the discussion